

ABC of HIV and AIDS

SIXTH EDITION

Edited by Michael W. Adler, Simon G. Edwards, Robert F. Miller,
Gulshan Sethi and Ian Williams



 WILEY-BLACKWELL

www.abcbookseries.com

BMJ | Books

Table of Contents

[Series Page](#)

[Title Page](#)

[Copyright](#)

[Contributors](#)

[Preface](#)

[Chapter 1: Development of the Epidemic](#)

[Development of the epidemic \(Boxes 1.1 and 1.2\)](#)

[Acknowledgement](#)

[Further reading](#)

[Chapter 2: Immunology of HIV-1 Infection](#)

[Introduction](#)

[Primary infection](#)

[Antiviral host immune responses](#)

[HIV-1 evasion of host immunity](#)

[Immunodeficiency](#)

[The response to cART](#)

[Further reading](#)

[Chapter 3: Viral Assays Used in the
Diagnosis and Management of HIV](#)

Infection

The diagnosis of HIV infection

The window period

Laboratory-based HIV screening tests

Western blot and line immunoassay

Rapid point-of-care HIV screening tests

Serology tests to detect recent HIV-1 infection

Virology tests for HIV detection and characterization

Viral load

HIV proviral DNA testing

Antiretroviral drug resistance

HIV-1 tropism

Further reading

Chapter 4: HIV Testing: Strategies to Prevent Late Diagnosis

Introduction

Who to test for HIV

Frequency of HIV testing

Which test to use

Pre-test discussion (Box 4.3)

Giving HIV test results

Summary

Further reading

Chapter 5: Clinical Staging and Natural History of Untreated HIV Infection

Introduction

[Primary HIV infection \(PHI\)](#)

[Asymptomatic infection](#)

[Symptomatic HIV infection before the development of AIDS](#)

[Constitutional symptoms](#)

[HIV and haematological problems](#)

[Non-AIDS diagnoses for which cART has treatment benefit irrespective of CD4 count](#)

[Risk of progression and the value of surrogate markers](#)

[Further reading](#)

[Chapter 6: Routine Assessment and Follow-up of the Newly Diagnosed HIV-positive Individual](#)

[Introduction](#)

[Interventions and discussion](#)

[Follow-up](#)

[Further reading](#)

[Chapter 7: Tumours in HIV](#)

[Introduction](#)

[AIDS-defining malignancies](#)

[Non-AIDS-defining malignancies](#)

[Further reading](#)

[Chapter 8: The Lung and HIV](#)

[Infections](#)

[Malignant conditions](#)

[Non-malignant, non-infectious conditions](#)
[Further reading](#)

[Chapter 9: HIV and Tuberculosis Co-infection](#)

[Background and epidemiology](#)
[Presentation and diagnosis of active disease](#)
[Treatment](#)
[Immune reconstitution inflammatory syndrome](#)
[TB control](#)
[Further reading](#)

[Chapter 10: The Gut and HIV](#)

[Introduction](#)
[Dysphagia and odynophagia](#)
[Nausea and vomiting](#)
[Diarrhoea](#)
[Further reading](#)

[Chapter 11: Viral Hepatitis and Liver Disease](#)

[Introduction](#)
[Hepatitis B co-infection](#)
[Hepatitis C co-infection](#)
[Immune reconstitution](#)
[Liver disease in an HIV-infected patient](#)
[Management of end-stage liver disease](#)
[Conclusions](#)
[Further reading](#)

Chapter 12: Neurological Manifestations

Introduction

Primary HIV seroconversion illness

Asymptomatic HIV disease

Advanced HIV disease

Peripheral nerve disorders in HIV infection

Neurological IRIS syndromes

Further reading

Chapter 13: The Eye and HIV

Introduction

Non-infectious HIV retinopathy

Ocular infection associated with HIV

Malignancy associated with HIV

Drug-induced ocular disease

Further reading

Chapter 14: The Skin and HIV

Introduction

Seborrhoeic dermatitis

Kaposi sarcoma

Pruritic papular eruption/eosinophilic folliculitis

Nodular prurigo

Drug rashes

Human papillomavirus (HPV)

Molluscum contagiosum

Herpes simplex virus

Candidiasis

Tinea infections

[Scabies](#)

[Syphilis](#)

[Penicillium marneffeii, Cryptococcus neoformans,](#)

[Histoplasma capsulatum](#)

[Conclusions](#)

[Further reading](#)

[Chapter 15: The Kidney and HIV](#)

[Introduction](#)

[Evaluating renal disease in HIV](#)

[Acute renal failure](#)

[HIV-associated nephropathy](#)

[Immune complex kidney disease](#)

[Antiretroviral drugs and the kidney](#)

[Renal monitoring in HIV infection](#)

[Renal replacement therapy](#)

[Further reading](#)

[Chapter 16: Sexually Transmitted Infections and HIV](#)

[HIV as an STI](#)

[STIs as a cofactor in HIV transmission](#)

[HIV and STI co-infection](#)

[Diagnosis and management of STIs](#)

[Further reading](#)

[Chapter 17: Women and HIV](#)

[Psycho-social issues](#)

[Natural history](#)

[Pregnancy management in the developed world](#)
[Pregnancy management in the developing world](#)
[Gynaecological care](#)
[Further reading](#)

[Chapter 18: HIV Infection in Children](#)

[Epidemiology](#)
[Prevention of mother-to-child transmission](#)
[Management](#)
[Supportive care](#)
[Further reading](#)

[Chapter 19: Antiretroviral Drugs](#)

[Reverse transcriptase inhibitors](#)
[Protease inhibitors](#)
[Integrase inhibitors](#)
[Chemokine receptor antagonists](#)
[Fusion inhibitors](#)
[Other treatment modalities](#)
[Treatment of chronic adult infection](#)
[When to start therapy \(Table 19.2\)](#)
[Choice of therapy](#)
[Antiretroviral regimens](#)
[Further reading](#)

[Chapter 20: Pharmacopoeia of Treatments](#)

[The role of cART after diagnosis of an opportunistic infection](#)
[Further reading and resources](#)

Chapter 21: Psychological and Mental Health Issues

Psychological wellbeing

Psychological sequelae

Adjustment to diagnosis

Physical health

Treatment regimens

Changes to body shape

HIV-associated neurocognitive disorders

Recognition of psychological symptomatology

Psychological Interventions

Factors impacting on living with HIV

Prevention

Further reading

Chapter 22: Strategies for Preventing HIV Transmission

Introduction

Targeted HIV education

Sexual transmission

Behavioural Interventions

Biomedical and treatment interventions

Risk compensation

Inclusion of people with HIV

High-quality sexual health services

HIV testing

Conclusion

Further reading

Chapter 23: Patient and Community Perspective

Garry Brough

Namatovu Lubega

Late diagnosis

Care and treatment outside of the HIV setting and its implications for HIV patients and their doctors

HIV testing for children

Social and psychological impact: examples of good practice

Chapter 24: The Role of Patient Engagement

Introduction

How can services engage patients? (Box 24.1)

What are the advantages for patients and care providers?

Care providers

Peer support

Representation at management meetings

Workshops

Forums

Newly diagnosed courses

Social events





Conclusions

Index

Advertisement Page

ABC series

An outstanding collection of resources – written by specialists for non-specialists



The ABC series contains a wealth of indispensable resources for GPs, GP registrars, junior doctors, doctors in training and all those in primary care

- ▶ **Now fully revised and updated**
- ▶ **Highly illustrated, informative and a practical source of knowledge**
- ▶ **An easy-to-use resource, covering the symptoms, investigations, treatment and management of conditions presenting in day-to-day practice and patient support**
- ▶ **Full colour photographs and illustrations aid diagnosis and patient understanding of a condition**

For more information on all books in the ABC series, including links to further information, references and links to the latest official guidelines, please visit:

www.abcbookseries.com

 **WILEY-BLACKWELL**

BMJ Books

ABC^{of}

HIV and AIDS

Sixth Edition

EDITED BY

Michael W. Adler

Emeritus Professor of Genitourinary Medicine/Sexually Transmitted Diseases
University College London Medical School
London, UK

Simon G. Edwards

Consultant GU/HIV Physician
Camden Provider Services
Mortimer Market Centre
London, UK

Robert F. Miller

Professor, Reader in Clinical Infection and Honorary Consultant Physician
University College London Medical School
London, UK

Gulshan Sethi

Consultant Physician in Sexual Health and HIV
Guy's and St Thomas' NHS Foundation Trust
London, UK

Ian G. Williams

Senior Lecturer and Honorary Consultant Physician
University College London Medical School
London, UK

 **WILEY-BLACKWELL**
A John Wiley & Sons, Ltd., Publication

BMJ|Books

This edition first published 2012 © 2012 by Blackwell
Publishing Ltd.

BMJ Books is an imprint of BMJ Publishing Group Limited,
used under licence by Blackwell Publishing which was
acquired by John Wiley & Sons in February 2007. Blackwell's
publishing programme has been merged with Wiley's global
Scientific, Technical and Medical business to form Wiley-
Blackwell.

Registered office: John Wiley & Sons, Ltd, The Atrium,
Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ,
UK

The Atrium, Southern Gate, Chichester, West Sussex, PO19
8SQ, UK

111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer
services and for information about how to apply for
permission to reuse the copyright material in this book
please see our website at www.wiley.com/wiley-blackwell

The right of the author to be identified as the author of this
work has been asserted in accordance with the UK
Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be
reproduced, stored in a retrieval system, or transmitted, in
any form or by any means, electronic, mechanical,
photocopying, recording or otherwise, except as permitted
by the UK Copyright, Designs and Patents Act 1988, without
the prior permission of the publisher.

Designations used by companies to distinguish their
products are often claimed as trademarks. All brand names
and product names used in this book are trade names,
service marks, trademarks or registered trademarks of their

respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or

extended by any promotional statements for this work.
Neither the publisher nor the author shall be liable for any
damages arising herefrom.

First published 1987

Second edition 1991

Third edition 1993

Fourth edition 1997

Fifth edition 2001

Library of Congress Cataloging-in-Publication Data

ABC of HIV and AIDS / edited by Michael W. Adler ... [et al.].
- 6th ed.

p. ; cm. - (ABC series)

Rev. ed. of: ABC of AIDS / edited by Michael W. Adler. 5th ed.
2001.

Includes bibliographical references and index.

ISBN 978-1-4051-5700-1 (pbk. : alk. paper)

I. Adler, Michael W. II. ABC of AIDS. III. Series: ABC series
(Malden, Mass.)

[DNLN: 1. Acquired Immunodeficiency Syndrome. 2. AIDS-
Related Opportunistic Infections. 3. HIV Infections. WC 503]

616.97'92-dc23

2011049093

A catalogue record for this book is available from the British
Library.

Wiley also publishes its books in a variety of electronic
formats. Some content that appears in print may not be
available in electronic books.

Contributors

Michael W. Adler

Emeritus Professor of Genitourinary Medicine/Sexually Transmitted Diseases, University College London Medical School, London, UK

David Asboe

Consultant Physician, Chelsea and Westminster Hospital, London, UK

Paul Benn

Consultant Physician, Mortimer Market Centre, London, UK

John Booth

Specialty Registrar in Nephrology, University College London Centre for Nephrology, Royal Free Hospital, London, UK

Mark Bower

Professor, Department of Oncology, Chelsea and Westminster Hospital, London, UK

Ronan Breen

Consultant Physician, Guy's and St Thomas' Hospital, London, UK

Garry Brough

Bloomsbury Clinic, Mortimer Market Centre, London, UK

John Connolly

Consultant Nephrologist and Honorary Senior Lecturer, Royal Free Hospital, London, UK

Sarah Doffman

Consultant Respiratory Physician, Brighton and Sussex University Hospitals NHS Trust, Royal Sussex County Hospital, Brighton, UK

Simon G. Edwards

Consultant GU/HIV Physician, Camden Provider Services, Mortimer Market Centre, London, UK

Emma Fox

Consultant Physician in Genitourinary Medicine, Kent Community Health Trust, Gate Clinic, Kent and Canterbury Hospital, Canterbury, UK

Patrick French

Consultant Physician in Genitourinary Medicine, Mortimer Market Centre, London, UK

Brian Gazzard

Professor, Imperial College London, London, UK

Anna Maria Geretti

Professor of Virology, Institute of Infection & Global Health, University of Liverpool, London, UK

Richard Gilson

Senior Clinical Lecturer, Centre for Sexual Health and HIV Research, University College London, London, UK

Graham J. Hart

Professor, Director of the Division of Population Health, Faculty of Biomedical Sciences, Centre for Sexual Health and HIV Research, University College London, London, UK

Barbara Hedge

Head of Psychology, St Helens and Knowsley Teaching Hospitals NHS Trust, Merseyside, UK

Elisabeth Higgins

Consultant, Department of Dermatology, Kings College Hospital, London, UK

John Imrie

Assistant Director, Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa; Principal Research Associate,

Centre for Sexual Health and HIV Research, University College London, London, UK

Sue Lightman

Professor of Clinical Ophthalmology, Moorfields Eye Hospital, London, UK

Marc Lipman

Senior Lecturer, Royal Free Hospital, University College London, London, UK

Namatovu Lubega

Patient Representative, London, UK

William Lynn

Consultant Physician in Infectious Diseases, Ealing Hospital, London, UK

Hadi Manji

Consultant Physician, National Hospital for Neurology, Queen Square, London, UK

Paddy McMaster

Consultant in Paediatric Infectious Diseases, North Manchester General Hospital, Manchester, UK

Danielle Mercey

Consultant Physician in Genitourinary Medicine, Central and North West London NHS Foundation Trust, London, UK

Robert F. Miller

Professor, Reader in Clinical Infection and Honorary Consultant Physician, University College London Medical School, London, UK

Adrian Mindel

Professor and Head of STI Research Centre, Westmead Hospital, Westmead, Sydney, NSW, Australia

June Minton

Lead Pharmacist HIV/GUM and Infectious Diseases, University College London Hospitals NHS Foundation

Trust, Mortimer Market Centre, London, UK

Rachael Morris-Jones

Consultant Dermatologist, Department of Dermatology, Kings College Hospital, London, UK

Mark Nelson

Consultant Physician, Chelsea and Westminster Hospital, London; Senior Lecturer, Imperial College London, London, UK

Mahdad Noursadeghi

Senior Lecturer, University College London, Honorary Consultant University College Hospital, London, UK

Adrian Palfreeman

Consultant, University Hospitals of Leicester, Leicester, UK

Felicity Perrin

Consultant Physician, King's College Hospital, London, UK

Deenan Pillay

Professor of Virology, University College London; Honorary Consultant Virologist at University College London Hospital, University College London, London, UK

Huw Price

Clinical Research Fellow, University College London, London, UK

Chris Sandford

Patient Representative, Mortimer Market Centre, London, UK

Gulshan Sethi

Consultant Physician in Sexual Health and HIV, Department of Sexual Health, Guy's and St Thomas' NHS Foundation Trust, London, UK

Suzy Stokes

Emergency Medicine Trainee, Oxfordshire Deanery, UK

Binta Sultan

Academic Clinical Fellow in HIV and GU Medicine,
University College London, Mortimer Market Centre,
London, UK

Melinda Tenant-Flowers

Consultant in GU and HIV Medicine at King's College
Hospital, Honorary Senior Lecturer at King's College
London Medical School, London, UK

Paola Vitiello

Research Assistant, Department of Virology, University
College London Royal Free Hospital, London, UK

Laura Waters

Consultant Physician, Mortimer Market Centre, London,
UK

Chris Wilkinson

Lead Consultant in Sexual and Reproductive Healthcare,
Central and North West London NHS Foundation Trust,
Margaret Pyke Centre, London, UK

Ian G. Williams

Senior Lecturer and Honorary Consultant Physician,
University College London Medical School, London, UK

Christine Younan

Clinical Fellow, Moorfields Eye Hospital, London UK and
Consultant Ophthalmologist, Westmead and Sydney Eye
Hospitals, Sydney, Australia

Preface

It is now over 30 years since the first recognized cases of AIDS were reported in the USA. There are estimated to be over 30 million persons living with HIV worldwide. Closer to home, the Health Protection Agency estimated that the number of individuals living with HIV in the UK will exceed 100 000 for the first time in 2012. There have been major advances in HIV therapy and where access to appropriate treatment and care is available, the clinical picture has evolved from a terminal illness to a manageable life-long chronic condition. In resource rich settings the major cause of death is due to the sequelae of late diagnosis. In the UK, it is estimated that a quarter of individuals with HIV are unaware of their infection. In addition, approximately half continue to be diagnosed with HIV at a late stage of infection. Early diagnosis of HIV is paramount, delivering both individual health gains, i.e. prevention of opportunistic infections with associated morbidity and mortality, and public health benefits in the prevention of HIV transmission through behaviour modification.

Following HIV diagnosis in the UK, we can be reassured that the quality of HIV care received is high. Based on London data, 80% of newly diagnosed patients were seen in an HIV clinic within 1 month of diagnosis; 90% had an undetectable viral load (less than 50 copies/mL) 1 year after starting therapy; and 93% of those in care for more than a year had a CD4 count above 200 cells per mm³. Antiretroviral regimens have become more convenient to take with the advent of coformulated medications and greater tolerability. HIV-infected patients spend most of their time out of hospital and in the community. It is likely that

primary care will play a greater role in the testing and subsequent management of HIV-infected individuals.

The aim of the sixth edition of the *ABC of HIV/AIDS* is to provide those healthcare professionals not routinely dealing with HIV-infected patients to develop an up-to-date knowledge base and feel more skilled and comfortable about caring for these patients.

This revised edition not only contains updated chapters but has new sections which reflect the latest recommendations on HIV testing, routine monitoring, antiretroviral treatment and the patient's perspective.

Chapter 1

Development of the Epidemic

B. Sultan¹ and M. W. Adler²

¹University College London, Mortimer Market Centre,
London, UK

²University College London Medical School, London, UK

Overview

The commonest mode of transmission of the virus is through sexual intercourse

The growth of the epidemic has appeared to stabilize
HIV continues to exhort a huge public health and economic burden

In 2009, there were 33.3 million people living with HIV worldwide

Sub-Saharan Africa has experienced a disproportionate burden of the global HIV epidemic

10 million people who are eligible for treatment under World Health Organization guidelines are still in need of treatment

Development of the epidemic (Boxes 1.1 and 1.2)

The first recognized cases of the acquired immune deficiency syndrome (AIDS) occurred in the summer of 1981 in the USA. Reports began to appear of *Pneumocystis carinii* (now known as *jirovecii*) pneumonia and Kaposi sarcoma in young men, who it was subsequently realized were both homosexual and immunocompromised. Even though the condition became known early on as AIDS, its cause and modes of transmission were not immediately obvious. The virus, human immunodeficiency virus (HIV), now known to cause AIDS in a proportion of those infected, was discovered in 1983. Subsequently a new variant has been isolated in patients with West African connections, HIV-2.

Box 1.1 Early history of the HIV epidemic

- 1981 Cases of *Pneumocystis carinii* pneumonia and Kaposi sarcoma in the USA
- 1983 Virus discovered
- 1984 Development of the antibody test
- 1987 Introduction of zidovudine therapy
- 1995 Formation of United Nations Programme on AIDS (UNAIDS)
- 1996 Introduction of highly active antiretroviral therapy (HAART)
- 2003 The '3 by 5' campaign is launched to widen access to treatment

Box 1.2 HIV epidemic—the bottom line

UN Millennium Development Goal Six

- Target **6A**. Have halted by 2015 and begun to reverse the spread of HIV/AIDS
- Target **6B**. Achieve, by 2010, universal access to treatment for HIV/AIDS for all those who need it.

‘Growth in investment for the AIDS response has flattened for the first time in 2009. Stigma, discrimination, and bad laws continue to place roadblocks for people living with HIV and people on the margins.... This new fourth decade of the epidemic should be one of moving towards efficient, focused and scaled-up programmes to accelerate progress for Results. Results. Results’

Michel Sidibé, Executive Director UNAIDS, UNAIDS Report on the Global AIDS Epidemic 2010

Thirty years on and with the introduction of combination antiretroviral therapy (cART), where it is widely available, the clinical picture of HIV has changed from a fatal illness to that of a chronic condition. There has been an increase in the number of people living with diagnosed HIV as a result of fewer deaths from AIDS and ongoing high rates of HIV diagnosis. In developed countries, where cART has been available from its inception, an ageing cohort is now seen, and people with HIV are living near-normal life expectancies. Consequent to this has arisen the challenges of managing the co-morbidities associated with age and the long-term consequences of cART. Despite this, more than 10 million people worldwide who require cART are not able to access it, and HIV continues to exhort a huge public health and economic burden. The last decade has seen consistent global efforts to address health, development and the HIV epidemic, starting with the United Nations (UN) Millennium Development Goals (MDGs). Despite extensive progress, many countries have failed to achieve MDG Six, which is in part to halt and reverse the spread of HIV (Box 1.2)

Transmission of the virus (Box 1.3)

HIV has been isolated from semen, cervical secretions, lymphocytes, cell-free plasma, cerebrospinal fluid, tears, saliva, urine and breast milk. This does not mean, however, that these fluids all transmit infection, as the concentration of virus in them varies considerably.

Box 1.3 Transmission of the virus

Sexual intercourse

- anal
- vaginal
- oral

Contaminated needles

- intravenous drug users
- needlestick injuries

Mother to child

- *in utero*
- at birth
- breastfeeding

Tissue donation

- blood transfusion
- organ transplantation

Particularly infectious are semen, blood and possibly cervical secretions. Infection can occur after mucosal exposure to infected blood or body fluids.

The commonest mode of transmission of the virus throughout the world is through sexual intercourse. Unprotected anal and vaginal intercourse carry the highest risk of transmission, and the promotion of condom use has been the focus of prevention efforts.

Transmission also occurs through the sharing or reuse of contaminated needles by injecting drug users, which continues to drive the epidemic in Eastern Europe.

Transmission from mother to child occurs *in utero*, during labour and through breastfeeding. Transmission rates can be between 15% and 45% without intervention, and less than 5% with effective interventions. Mother-to-child transmission (MTCT) of HIV still significantly contributes to child mortality worldwide. However, the increase in access to services for preventing MTCT has led to fewer children being born with HIV. Use of cART during pregnancy, and at the time of birth, has been the mainstay of intervention strategies (see Chapters 17 and 18). In the UK, universal antenatal screening and access to cART have virtually eliminated MTCT. Globally, an estimated 370 000 children were newly infected with HIV in 2007, a fall of 24% from 5 years previously. UNAIDS called for the elimination of new paediatric HIV infections by 2015. It recommends that countries adopt a policy that HIV-positive mothers or their infants take ART while breastfeeding to prevent HIV transmission.

Contaminated blood products have previously contributed to the transmission of HIV, but universal screening has almost eliminated this mode of transmission in developed countries. Healthcare workers can rarely be infected through needlestick injuries and skin and mucosal exposure to infected blood or body fluids.

Growth and size of the epidemic (Table [1.1](#), Figure [1.1](#))

The growth of the epidemic has appeared to stabilize. Globally, there are fewer AIDS-related deaths and a steady decline in the number of new HIV infections since the late 1990s. In 2009, there were 33.3 million people living with HIV. There were 2.6 million new infections, which is 21% fewer than in 1997 (3.2 million) when the number of new infections reached its peak. HIV remains undiagnosed in


40% of people. The HIV incidence in 33 countries has fallen by 25% between 2001 and 2009, with 22 of these countries being in sub-Saharan Africa. However, in seven countries there has been an increase of more than 25% in the same time period. These include five countries in Eastern Europe and Central Asia.

Table 1.1 Regional HIV and AIDS statistics 2009.

	Adults and children living with HIV	Adults and children newly infected with HIV	Adult prevalence (15–49 years) (%)	Adult & child deaths due to AIDS
Sub-Saharan Africa	22.5 million (20.9 million–24.2 million)	1.8 million (1.6 million–2.0 million)	5.0 (4.7–5.2)	1.3 million (1.1 million–1.5 million)
Middle East and North Africa	460 000 (400 000–530 000)	75 000 (61 000–92 000)	0.2 (0.2–0.3)	24 000 (20 000–27 000)
South and South-East Asia	4.1 million (3.7 million–4.6 million)	270 000 (240 000–320 000)	0.3 (0.3–0.3)	260 000 (230 000–300 000)
East Asia	770 000 (560 000–1.0 million)	82 000 (48 000–140 000)	0.1 (0.1–0.1)	36 000 (25 000–50 000)
Central and South America	1.4 million (1.2 million–1.6 million)	92 000 (70 000–120 000)	0.5 (0.4–0.6)	58 000 (43 000–70 000)
Caribbean	240 000 (220 000–270 000)	17 000 (13 000–21 000)	1.0 (0.9–1.1)	12 000 (8500–15 000)
Eastern Europe and Central Asia	1.4 million (1.3 million–1.6 million)	130 000 (110 000–160 000)	0.8 (0.7–0.9)	76 000 (60 000–95 000)
Western and Central Europe	820 000 (720 000–910 000)	31 000 (23 000–40 000)	0.2 (0.2–0.2)	8500 (6800–19 000)
North America	1.5 million (1.2 million–2.0 million)	70 000 (44 000–130 000)	0.5 (0.4–0.7)	26 000 (22 000–44 000)
Oceania	57 000 (50 000–64 000)	4500 (3400–6000)	0.3 (0.2–0.3)	1400 (<1000–2400)
Total	33.3 million (31.4 million–35.3 million)	2.6 million (2.3 million–2.8 million)	0.8 (0.7–0.8)	1.8 million (1.6 million–2.1 million)

The ranges around the estimates in this table define the boundaries within which the actual numbers lie, based on the best available information.
Source: UNAIDS Report on the Global AIDS Epidemic 2010.

Figure 1.1 Estimated adult and child deaths from AIDS, 2009.



Even though North America and Europe experienced the first impact of the epidemic, infections with HIV are now seen throughout the world, and the major focus of the epidemic is in resource-poor countries.

UK, Western Europe and USA

The number of people living with HIV in North America and Western and Central Europe has increased, with a 30% rise since 2001, and reached an estimated 2.3 million people in 2009. Heterosexual transmission represents about 50% of new HIV infections. In 2007, almost 17% of these new infections were among people from countries with generalized epidemics. The data are indicative of a resurgence of the HIV epidemic among men who have sex with men (MSM) in North America and Western Europe. Between 2000 and 2006 there was an 86% rise in the annual number of new HIV diagnoses in this risk group.

In the UK, the Health protection Agency (HPA) predicts that by 2012 the number of people living with HIV will continue to rise and reach 100 000. In 2009 there was an estimated